Amylyx Pharmaceuticals In... (AMLX)
NASDAQ: AMLX
· Real-Time Price · USD
14.52
0.70 (5.07%)
At close: Sep 26, 2025, 3:59 PM
14.80
1.93%
After-hours: Sep 26, 2025, 06:34 PM EDT
5.07% (1D)
| Bid | 14.04 |
| Market Cap | 1.29B |
| Revenue (ttm) | -249K |
| Net Income (ttm) | -187.6M |
| EPS (ttm) | -2.49 |
| PE Ratio (ttm) | -5.83 |
| Forward PE | -9.8 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 14.87 |
| Volume | 2,346,278 |
| Avg. Volume (20D) | 1,813,292.7 |
| Open | 13.96 |
| Previous Close | 13.82 |
| Day's Range | 13.69 - 14.60 |
| 52-Week Range | 2.60 - 14.60 |
| Beta | -0.44 |
| Ex-Dividend Date | n/a |
About AMLX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AMLX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AMLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
+12.56%
Amylyx Pharmaceuticals shares are trading higher. ...
Unlock content with
Pro Subscription
2 months ago
+9.51%
Amylyx Pharmaceuticals shares are trading higher after the company highlighted the efficacy and 24-hour coverage of Avexitide 90 mg daily and announced it supports advancing to Phase 3 of the LUCIDITY trial.
